What is REGN stock price today?

REGN (Regeneron Pharmaceuticals Inc) stock is trading at $659.92 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is REGN stock going up or down today?

REGN stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy REGN stock now?

The decision to buy REGN depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is REGN a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for REGN based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is REGN stock overvalued or undervalued?

REGN currently trades at a P/E ratio of 13.91, which may suggest attractive valuation. Our DCF calculator provides intrinsic value estimates to help determine if REGN is fairly priced.

What is REGN's P/E ratio?

REGN has a price-to-earnings (P/E) ratio of 13.91, which measures how much investors are willing to pay per dollar of earnings. Compare this to industry peers and historical averages for context.

What is REGN's market cap?

REGN (Regeneron Pharmaceuticals Inc) has a market capitalization of $59.10 billion, making it a mid-cap stock.

What is REGN's price to book ratio?

Price-to-book ratio for REGN is available on our dashboard along with other valuation metrics.

Does REGN pay dividends?

Yes, REGN pays dividends with a current yield of 0.67%. Dividend payments provide income for investors in addition to potential stock price appreciation.

What is REGN's dividend yield?

REGN's dividend yield is 0.67%, calculated as annual dividends divided by the current stock price. This represents the annual return from dividends alone.

Is REGN stock a good long-term investment?

REGN's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is REGN's revenue growth rate?

Revenue growth data for REGN is available on our dashboard with detailed financial statement analysis.

Profitability metrics for REGN are available on our dashboard with complete income statement analysis.

What are the risks of investing in REGN?

Key risks for REGN include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does REGN compare to its competitors?

Compare REGN to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize REGN's performance and positioning.

What is REGN's stock price target for 2026?

Our AI model provides price targets for REGN based on fundamental analysis: Bull case $857.90 (+30%), Base case $758.91 (+15%), Bear case $593.93 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about REGN?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for REGN. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is REGN's next earnings report?

REGN reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

REGN - Regeneron Pharmaceuticals Inc

NYSE * Healthcare * Biotechnology

$659.92

$-3.17 (-0.48%)

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc (REGN) common stock

Price Chart

Loading chart...

REGN Key Statistics

Market Cap

$59.10B

P/E Ratio

13.91

Dividend Yield

0.67%

How REGN Compares to Peers

REGN has the lowest P/E ratio in Biotechnology, suggesting it may be the most undervalued

P/E Rank

of 5

Margin Rank

N/A

of 0

Growth Rank

N/A

of 0

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
REGN(This stock)	$59.10B	13.9	0%	0.0%	-
AMGNAmgen Inc	$188.67B	24.3	0%	0.0%	vs AMGN
GILDGilead Sciences	$160.15B	17.5	0%	0.0%	vs GILD
VRTXVertex Pharmaceuticals	$106.87B	29.7	0%	0.0%	vs VRTX
BIIBBiogen Inc	$29.33B	21.4	0%	0.0%	vs BIIB
MRNAModerna Inc	$24.52B	N/A	0%	0.0%	vs MRNA

Data Updated: July 14, 2026 at 2:14 PM EDT

Ready to invest in REGN?

Commission-free trading available. Affiliate links.

REGN Lician Score

10% confidence

6.0/10

Good

REGN has a Lician Score of 6/10 (Good). Strengths: Growth.

value

5.0

growth

8.0

quality

5.0

momentum

5.0

safety

5.0

The Lician Score is a comprehensive 1-10 rating that evaluates REGNacross five key dimensions: Value (valuation relative to sector),Growth (revenue and earnings trajectory),Quality (profitability and balance sheet strength),Momentum (price trends and analyst sentiment), andSafety (volatility and risk metrics).

REGN Financial Snowflake

5-axis analysis across key investment dimensions

5.6/10

Neutral

5.0

Value

Valuation vs. sector peers

8.0

Growth

Revenue & earnings trajectory

5.0

Quality

Profitability & moat strength

5.0

Momentum

Price trends & analyst sentiment

5.0

Safety

Financial stability & risk

Upcoming Events for REGN

Dashboard

Enter a ticker to analyze